Niemann-Pick disease, type A

Niemann-Pick disease, type A is a lysosomal genetic disease caused by autosomal recessive variants in SMPD1, acting through loss-of-function (biallelic; recessive). Within this volume's rankable burden cohort it sits at residual rank 2 of 23, where no disease-directed therapy alters its course. That order is a provisional [H]-grade prioritisation device, not a registry-locked ranking.

Niemann-Pick disease, type A is inherited as autosomal recessive and acts by loss-of-function (biallelic; recessive) ([H]). Its pre-treatment burden proxy is 0.8750 and, after the established therapy's efficacy offset e = 0.0000 is applied, its residual burden score is 0.8750 ([H]), placing it at residual rank 2 of 23.

Gene, inheritance, and molecular mechanism

Niemann-Pick disease, type A is inherited as Autosomal recessive inheritance [L] and is classified mechanistically as loss-of-function (biallelic; recessive) [H]. SMPD1 encodes acid sphingomyelinase. Biallelic loss of its activity lets sphingomyelin accumulate in lysosomes throughout the viscera and the nervous system (acid sphingomyelinase deficiency, ASMD).

Inheritance source: medgen:esummary:ModeOfInheritance:2026-06-17. Mechanism source: inference:recessive=>loss_of_function; basis=medgen_inheritance(recessive). These are observed, cited inputs; the inheritance and mechanism classification is the reproducible analysis layer (C-D1).

In-scope clinical involvement

Infantile neurovisceral ASMD presents with hepatosplenomegaly, failure to thrive, a cherry-red macula, and a rapidly progressive, fatal neurodegeneration in the first years of life.

Organ systems [L] from HPO phenotype.hpoa v2026-06-06 (OMIM 257200,607608); P-aspect terms rolled up to HP:0000118 organ-system categories via hp.obo.

Reproducible burden position

Of the five axes, 4 are scored (the rankability cut is ≥ 3 of 5); the pre-treatment composite is the renormalised mean over the scored axes, raw_burden = 0.8750. The registry-grade [L] axes here are onset, progression, severity, and disability (onset from the Orphanet AverageAgeOfOnset register / HPO; disability from the GBD 2013 disability-weights table).

All 4 scored axes for this disease are registry-grade [L]/[V]: its burden value is registry-locked (order_locked) and no longer rests on definition-only inference. The cohort order overall is still a provisional [H] prioritisation device, not a registry-locked ranking — this disease’s absolute rank depends on neighbours whose axes remain [H].

The natural-history registry passes have been run against Orphanet/Orphadata (CC BY 4.0, R6) and the openly published GBD 2013 disability-weights table (Salomon et al., CC BY, R7). R6 lifts onset to registry-grade [L] across most of the cohort (earliest AverageAgeOfOnset category, entity-anchored per ORPHAcode, Exact OMIM↔ORPHA only); R7 lifts disability to [L] where one dominant untreated sequela maps to a named GBD health state (published disability weight binned by declared cut-points), and independently corroborates a mortality axis from PMC survival literature where a quantitative disease-typical figure exists. Severity now lifts to registry [L] for the one disease whose dominant sequela carries a cited HPO Severity-modifier annotation (the HP:0012824 subtree, R8); for the rest the open HPO severity annotations are feature-level (using one feature as the disease tier would be a category error), so severity stays [H]/[O] with the obstacle named. Progression lifts to registry [L] where a cited PMC open-access source states a disease-level magnitude for the dominant untreated sequela and the frozen R3 tier function derives the tier from that verbatim sentence (R9, curated dominant-sequela join, non-spectrum); for the rest progression stays [H]/[O]. The OMIM clinical synopsis (the disease-level alternative) is API-key-gated and the key is unobtainable for an individual researcher — that path is removed, not guessed.

Established treatment and residual burden

The established disease-directed approach is supportive care; enzyme replacement (olipudase alfa) is approved for non-CNS ASMD only and does not alter the lethal neurologic course of type A. Mechanistically: ERT addresses visceral sphingomyelin storage but the neuronopathic course is not amenable (cited) [H].

Its effect on natural history is classified none, mapping to an efficacy offset e = 0.0000 and a residual factor R_treat = 1.0000. Applied to the pre-treatment proxy this gives the residual burden score 0.8750, moving the disease from raw rank 2 to residual rank 2 (shift 0).

Evidence tier: in-package cited MedGen clinical_definition [H] (matched treatment phrase: “Enzyme replacement”). Accession-dated [L] verification (FDA label / GeneReviews Management / OMIM / Orphanet) is deferred.

An evidence_status of none (e = 0) is a positive [H] finding that no disease-directed therapy alters the course — distinct from an open [O] gap. No cure is implied (constitution C-D3).